Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and Immunogenicity of Hecolin in Healthy Volunteers Over 65
NCT02417597Phase 4Completed
- Sponsor
- Xiamen Innovax Biotech Co., Ltd.
- Start
- Apr 2015
- Primary completion
- May 2016
- Modality
- Recombinant Protein Vaccines
- Countries
- 1
01
Overview
A Phase 4 trial of HEV 239 in hepatitis E (HEV), sponsored by Xiamen Innovax Biotech Co., Ltd.. Started Apr 2015; status: completed.
02
Drugs
HEV 239
03
Conditions
hepatitis E (HEV)
Beyond the preview
Go deeper on NCT02417597.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02417597.